---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000571"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:43:31.974836+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics promotes COO Nathan Dowden to President, effective Jan 1, 2024

## Summary
- Nathan J. Dowden promoted to President, retains COO role; Dipal Doshi continues as CEO.
- Salary increased to $480,000/year; target bonus raised to 45%.
- Granted 60,000 RSUs vesting 50% on 2nd anniversary and 50% on 3rd anniversary.
- Dowden has served as COO since Nov 2019 and has 30 years healthcare sector experience.

## SEC filing metadata
- accession: 0001104659-24-000571
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/0001104659-24-000571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/tm241489d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000571
- JSON: https://secwatch.observer/filing/0001104659-24-000571.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000571.txt

## Key facts
- Executive change
  Nathan J. Dowden was appointed as President and Chief Operating Officer at Entrada Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000110465924000571/0001104659-24-000571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.